What is Neurocrine Biosciences's market cap?

Neurocrine Biosciences (NBIX) has a market capitalization of $17.5B and trades on NASDAQ.

What is Neurocrine Biosciences's revenue and profitability?

Neurocrine Biosciences generated $3.1B in trailing twelve-month revenue with net income of $668.6M, representing a net margin of 21.6%. Gross margin stands at 98.2%, with free cash flow of $831.3M. These figures are based on the Q1 2026 filing.

Who are Neurocrine Biosciences's competitors?

Neurocrine Biosciences's key competitors include Bristol-Myers Squibb, Alzamend Neuro, Inc. Common Stock, Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Neurocrine Biosciences partner with?

Neurocrine Biosciences's notable partners include AbbVie Inc., Takeda Pharmaceutical Company Limited, Nxera Pharma UK Limited, and others.

Where is Neurocrine Biosciences headquartered?

Neurocrine Biosciences is headquartered in United States of America and employs approximately 1,448 people. It has been publicly traded since 1996.

Neurocrine Biosciences

NBIX

Market cap

$17.51B+29.4%

Revenue$3.1B+28.6%

Net income$668.6M+119%

Free cash flow$831.3M+68.9%

EPS (diluted)$6.49+120%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$814.5MBeat by $46.2M EPS$1.94Beat by $0.66

Read the full report

Next report

Jul 30, 2026 (In 2 days)

Revenue estimate$890.0M

EPS estimate$1.64

Financials

Q1 2026

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation & ratios

Valuation

See full

Market cap$17.51B+29.4%

Enterprise value$17.7B+33.6%

P/E26.2×-11.2×

P/S5.6×+0.5×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Segments

By segment

See full

Reportable Segment$814.5M+42.2%

By product

See full

Collaboration revenues$3.5M-60.7%

Competitors

By market cap

Bristol-Myers Squibb$125.61B+26.1%

Neurocrine Biosciences$17.5B+34.4%

Ultragenyx Pharmaceutical$2.7B+3.1%

XER

Xeris Biopharma Holdings, Inc.$1.5B+75.4%

Rigel Pharmaceuticals$681.2M+86.6%

Vanda Pharmaceuticals$322.3M+14.2%

SCN

Scienture Holdings, Inc.$15.9M-40.3%

Alzamend Neuro, Inc.$4.8M-44.6%

By revenue growth

Rigel Pharmaceuticals+47.6%

XER

Xeris Biopharma Holdings, Inc.+41.5%

Neurocrine Biosciences+28.6%

Ultragenyx Pharmaceutical+13.5%

Bristol-Myers Squibb+1.8%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Neurocrine Biosciences21.55%+8.9pp

Bristol-Myers Squibb15.01%+3.8pp

XER

Xeris Biopharma Holdings, Inc.3.81%+24.1pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

Profile

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for neurological, psychiatric, endocrine, and immunological disorders. The company's value proposition is centered on addressing significant unmet medical needs through a portfolio of approved treatments and a diversified pipeline of small molecules and biologics. Its primary revenue driver is a leading treatment for tardive dyskinesia and Huntington's disease chorea.

Competitive position

A leading neuroscience company with the first FDA-approved treatment for tardive dyskinesia and a dominant position in the VMAT2 inhibitor market.

GeographiesUnited States, Japan, Asia

Customer segmentsPatients, Healthcare Providers, Specialty Pharmacies

Business modelResearch and Development, Direct-to-market pharmaceutical sales, Licensing and Royalties

SuppliersThird-party contract manufacturers (CMOs), Active pharmaceutical ingredient (API) suppliers, Third-party logistics providers

CustomersSpecialty pharmacies, Pharmaceutical wholesalers, Hospitals and long-term care facilities, Endocrinology and neurology clinics

CountryUnited States of America

Listed1996

Employees1.4K

CEOKyle W. Gano

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteneurocrine.com

FilingsSEC EDGAR

Ask your AI about Neurocrine Biosciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's market cap?: Neurocrine Biosciences (NBIX) has a market capitalization of $17.5B and trades on NASDAQ.
What is Neurocrine Biosciences's revenue and profitability?: Neurocrine Biosciences generated $3.1B in trailing twelve-month revenue with net income of $668.6M, representing a net margin of 21.6%. Gross margin stands at 98.2%, with free cash flow of $831.3M. These figures are based on the Q1 2026 filing.
Who are Neurocrine Biosciences's competitors?: Neurocrine Biosciences's key competitors include Bristol-Myers Squibb, Alzamend Neuro, Inc. Common Stock, Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Neurocrine Biosciences partner with?: Neurocrine Biosciences's notable partners include AbbVie Inc., Takeda Pharmaceutical Company Limited, Nxera Pharma UK Limited, and others.
Where is Neurocrine Biosciences headquartered?: Neurocrine Biosciences is headquartered in United States of America and employs approximately 1,448 people. It has been publicly traded since 1996.